ducovest

XVIPF:OTO-Xvivo Perfusion Ab Ord (USD)

COMMON STOCK | Medical Devices | OTC Pink

Last Closing

USD 48.204

Change

0.00 (0.00)%

Market Cap

USD 0.22B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Xvivo Perfusion AB is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation.

Company Website : http://www.xvivoperfusion.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
SEMHF Siemens Healthineers AG

N/A

 USD 64.87B
SMMNY Siemens Healthineers AG ADR

N/A

 USD 63.28B
RYLPF Koninklijke Philips N.V

N/A

 USD 27.91B
SONVF Sonova Holding AG

N/A

 USD 21.25B
SNNUF Smith & Nephew plc

N/A

 USD 13.52B
WILLF Demant A/S

N/A

 USD 9.39B
GNGBF Getinge AB

N/A

 USD 5.77B
AMBBY Ambu A/S

N/A

 USD 4.99B
AMBFF Ambu A/S

N/A

 USD 4.99B
GGNDF GN Store Nord A/S

N/A

 USD 3.66B

ETFs Containing XVIPF

RUBY-U:CA RBC U.S. Banks Yield Inde.. 7.27 % 0.00 %

N/A

 N/A
ZWK:CA BMO Covered Call US Banks.. 6.67 % 0.00 %

N/A

 CAD 0.34B
IUS2:F iShares S&P U.S. Banks UC.. 4.18 % 0.00 %

N/A

 N/A
IUS2:XETRA iShares S&P U.S. Banks UC.. 4.18 % 0.00 %

N/A

 USD 0.33B
BNKS:LSE iShares S&P U.S. Banks 4.17 % 0.00 %

N/A

 N/A
FBU:CA 2.78 % 0.84 %

N/A

 N/A
KRS 2.30 % 0.95 %

N/A

 N/A
KRU 2.30 % 0.95 %

N/A

 N/A
MVIN 2.28 % 0.55 %

N/A

 N/A
RDVY First Trust Rising Divide.. 2.28 % 0.50 %

N/A

 USD 11.66B
KRE SPDR® S&P Regional Banki.. 2.19 % 0.35 %

N/A

 N/A
DPST Direxion Daily Regional B.. 1.73 % 1.02 %

N/A

 USD 0.87B
IXG iShares Global Financials.. 0.00 % 0.46 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 111.42% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 111.42% 93% A 94% A
Trailing 12 Months  
Capital Gain 61.76% 89% A- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.76% 89% A- 88% B+
Trailing 5 Years  
Capital Gain 162.12% 92% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 162.12% 92% A 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 36.65% 75% C 73% C
Dividend Return 36.65% 75% C 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 77.77% 45% F 38% F
Risk Adjusted Return 47.13% 95% A 83% B
Market Capitalization 0.22B 86% B+ 75% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.